ArticleNano letters2025
Silica Nanobottles Filled with Photo-cross-linked GelMA for the Sustained Release of Hydrophilic Biomacromolecules.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanobottles have garnered attention as a class of advanced carriers for drug delivery, because of their advantages, such as convenient loading, high capacity, and a well-defined wall for surface modification. However, strategies to achieve sustained release of hydrophilic biomolecules remain limited. Here, we report a hybrid delivery platform that integrates silica nanobottles with photo-cross-linked gelatin methacryloyl for the encapsulation and controlled release of proteins, enzymes, and polysaccharides. Upon cross-linking, the payloads show enhanced intracellular stability, with minimal release in A549 cells for up to 24 h. This system also enables control over release kinetics, with the half-life extendible to several weeks depending on the type and/or molecular weight of the payload. Importantly, released biomacromolecules retain structural and functional integrity, and delivery of nerve growth factor promotes robust neurite outgrowth from PC12 cells. This hybrid system provides a versatile and programmable platform for the long-term delivery of diverse hydrophilic therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.